Oncology Drug Reference Sheet: Lifileucel
Madeline Johnston, MSN, RN, OCN®
Voice
Description
On February 16, 2024, the U.S. Food and Drug Administration approved the first tumor-infiltrating lymphocyte cancer therapy for metastatic melanoma, lifileucel (Amtagvi™). Patients in the drug’s clinical trial experienced a significant decrease in tumor burden, and the median overall survival was 17.4 months.